Axovant Sciences Ltd.

Axovant is currently developing two novel compounds: RVT-101, a potent 5HT6 receptor antagonist, and nelotanserin, a highly potent and selective inverse agonist of the 5HT2A receptor.
Our near-term focus is to develop RVT-101 for the treatment of Alzheimer’s disease and dementia with Lewy bodies.
We are also beginning development of our second compound, nelotanserin, for the treatment of Lewy body dementia. In early 2016 we will initiate two separate Phase 2 studies of nelotanserin.